Operational Expansion in UK for Diagnostics Group

French clinical diagnostics specialist Novacyte (Paris) has announced updates on its near-term COVID-19 research and development (R&D) programmes to address rapidly evolving testing demands, particularly as SARS-CoV-2 continues to mutate around the world. The report includes information on progress with its lateral flow tests and PCR developments. Information on the company’s UK operational highlights were also disclosed.

Chief Executive Officer Graham Mullis said: “The continued development and expansion of our COVID-19 portfolio demonstrates Novacyt’s ability to match the rapid evolution of SARS-CoV-2 with real-time bioinformatics surveillance and accelerated product development. We remain committed to identifying patient needs and overcoming healthcare challenges today and in the years ahead as we continue to strengthen our position as a leading innovator in diagnostic testing.

“We are also pleased to be included in the PHE national framework, which allows PHE and NHS hospitals to purchase our accredited products without the need for direct contract awards. We look forward to the opportunity to expand our support of diagnostic testing in the UK through our established infrastructure and building a long-term future in this important market, as well as in international markets as we continue to invest in our direct commercial operations.”

The company has invested significantly in the UK market during the past 12 months and now has over 50 field specialists servicing the NHS across England, Wales, Scotland and Northern Ireland. In addition, its wholly owned subsidiaries Primerdesign and Microgen Bioproducts, have been included in the National Microbiology Framework for Diagnostic Goods and Services (Lot 1) published by PHE for a range of clinical products.

Further information online